Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FoTv for COVID-19 Outpatients
NCT04667247Phase 2Completed
- Start
- Dec 2020
- Primary completion
- Mar 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tivozanib in coronavirus disease 2019 (COVID-19). Primary endpoint: Total Protein Normal to Abnormal Transition at 14 days. Started Dec 2020; status: completed.
02
Drugs
tivozanib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04667247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667247.